Marion E. Reid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marion E. Reid has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Kim Hue‐Roye
Laboratory of Immunochemistry New York Blood Center New York New York
12 shared publicationsChristine Lomas‐Francis
Laboratory of Immunochemistry New York Blood Center New York New York
11 shared publicationsRandall W. Velliquette
Laboratory of Immunochemistry New York Blood Center New York New York
11 shared publicationsChristine Halter Hipsky
From the Laboratory of Immunohematology and Genomics, New York Blood Center, Long Island City, New York; the National Molecular Blood Group and Platelet Antigen Testing Laboratory, American Red Cross, Philadelphia, Pennsylvania; the Laboratory of Immunochemistry, New York Blood Center, New York, New York; and Immucor, Inc., Norcross, Georgia
6 shared publicationsChristine Lomas-Francis
From the Laboratory of Immunochemistry, New York Blood Center, New York, New York; the Laboratory of Immunohematology and Genomics, New York Blood Center, Long Island City, New York; the Rh Laboratory, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada; and the Specialized Laboratory Services, South African National Blood Service, Pinetown, KwaZulu‐Natal, South Africa
6 shared publicationsKim Hue-Roye
From the Laboratory of Immunochemistry, New York Blood Center, New York, New York; the Laboratory of Immunohematology and Genomics, New York Blood Center, Long Island City, New York; the Rh Laboratory, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada; and the Specialized Laboratory Services, South African National Blood Service, Pinetown, KwaZulu‐Natal, South Africa
4 shared publications
Latest Publications
- 1 April 2014
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 52 (4) , 195-202
Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease
- 1 April 2014
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 52 (4) , 195-202
Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease
- 13 June 2013
- Published by Wiley in Transfusion
- Vol. 54 (2) , 398-404
Alleles of the LAN blood group system: molecular and serologic investigations
Background: Anti‐Lan has been implicated in hemolytic transfusion reactions and hemolytic disease of the fetus and newborn. The LAN blood group system is encoded by ABCB6, whose gene product, ABCB6, belongs to the ATP‐binding cassette (ABC) efflux transporter superfamily. The purpose of this study was to characterize additional alleles by analyzing DNA from 14 (13 unrelated) subjects whose red blood cells were serologically defined as Lan−, Lan+w/−, or Lan+w.Study Design and Methods: Genomic DNA was extracted from blood samples recovered from liquid nitrogen storage. Intronic primers flanking each of the ABCB6 coding exons were used for polymerase chain reaction amplification. Amplicons were sequenced and analyzed by standard methods.Results: Among the study subjects, we identified five alleles (one with a nonsense change, three with frameshifts, one with a missense change) that encode the Lan− phenotype and four alleles (with missense changes) encoding either Lan+w or Lan+w/− phenotypes.Conclusions: Of the nine alleles we identified, three were novel and six were previously documented in the dbSNP. Of these six, only one allele was previously associated with Lan negativity. To date, 19 ABCB6 alleles that encode Lan− or Lan+w/−, or Lan+w phenotypes have been described.
- 13 June 2013
- Published by Wiley in Transfusion
- Vol. 54 (2) , 398-404
Alleles of the LAN blood group system: molecular and serologic investigations
Background: Anti‐Lan has been implicated in hemolytic transfusion reactions and hemolytic disease of the fetus and newborn. The LAN blood group system is encoded by ABCB6, whose gene product, ABCB6, belongs to the ATP‐binding cassette (ABC) efflux transporter superfamily. The purpose of this study was to characterize additional alleles by analyzing DNA from 14 (13 unrelated) subjects whose red blood cells were serologically defined as Lan−, Lan+w/−, or Lan+w.Study Design and Methods: Genomic DNA was extracted from blood samples recovered from liquid nitrogen storage. Intronic primers flanking each of the ABCB6 coding exons were used for polymerase chain reaction amplification. Amplicons were sequenced and analyzed by standard methods.Results: Among the study subjects, we identified five alleles (one with a nonsense change, three with frameshifts, one with a missense change) that encode the Lan− phenotype and four alleles (with missense changes) encoding either Lan+w or Lan+w/− phenotypes.Conclusions: Of the nine alleles we identified, three were novel and six were previously documented in the dbSNP. Of these six, only one allele was previously associated with Lan negativity. To date, 19 ABCB6 alleles that encode Lan− or Lan+w/−, or Lan+w phenotypes have been described.
- 15 April 2013
- Published by Wiley in Transfusion
- Vol. 53 (9) , 1876-1883
Emily Cooley lecture 2012
Emily Cooley was a well-respected medical technologist and morphologist with a remarkable skill set. She was highly regarded both professionally and personally. The "Emily Cooley Lectureship and Award" was established to honor her in particular and medical technologists in general. This article first reviews the history of the Emily Cooley award and provides some of the reasons why it carries her name. Then, using two blood group systems, DO and JR, it illustrates how many discoveries regarding blood groups were dependent on access to techniques.
- 15 April 2013
- Published by Wiley in Transfusion
- Vol. 53 (9) , 1876-1883
Emily Cooley lecture 2012
Emily Cooley was a well-respected medical technologist and morphologist with a remarkable skill set. She was highly regarded both professionally and personally. The "Emily Cooley Lectureship and Award" was established to honor her in particular and medical technologists in general. This article first reviews the history of the Emily Cooley award and provides some of the reasons why it carries her name. Then, using two blood group systems, DO and JR, it illustrates how many discoveries regarding blood groups were dependent on access to techniques.
- 8 April 2013
- Published by Wiley in Transfusion
- Vol. 53 (11pt2) , 2872-2881
Molecular basis of two novel and related high‐prevalence antigens in the Kell blood group system, KUCI and KANT, and their serologic and spatial association with K11 and KETI
Background The numerous antigens in the Kell blood group system result from missense nucleotide changes in KEL. Antibodies to antigens in this system can be clinically important. We describe six probands whose plasma contained antibodies to high‐prevalence Kell antigens and discuss their relationship. Study Design and Methods Polymerase chain reaction amplification, direct sequencing, restriction fragment length polymorphism assays, hemagglutination, flow cytometry, and protein modeling were performed by standard methods. Results Proband 1 (KUCI) and her serologically compatible sister were heterozygous for a nucleotide change in Exon 11 (KEL*1271C/T; Ala424Val). Proband 2 (KANT) was heterozygous for KEL*1283G/T (Arg428Leu) and KEL*1216C/T (Arg406Stop) in Exon 11. Red blood cells (RBCs) from Proband 1 and her sister were not agglutinated by plasma from Proband 2; however, RBCs from Proband 2 were agglutinated by plasma from Proband 1. Probands 3, 4, 5, and 6 had the KEL*1391C>T change associated with the previously reported KETI– phenotype. Proband 5 was also homozygous for KEL*905T>C encoding the K11–K17+ phenotype. Hemagglutination studies revealed an association between KUCI, KANT, KETI, and K11. Protein modeling indicated that whereas Ala424 and Arg428 are clustered, Val302 and Thr464 are not. Conclusion Ala424 in the Kell glycoprotein is associated with the high‐prevalence Kell antigen, KUCI (ISBT 006032), which is detected by the antibody of Proband 1. Arg428 is associated with the high‐prevalence Kell antigen, KANT (ISBT 006033). The association between KUCI, KANT, KETI, and K11 and the results of protein modeling are discussed.
- 8 April 2013
- Published by Wiley in Transfusion
- Vol. 53 (11pt2) , 2872-2881
Molecular basis of two novel and related high‐prevalence antigens in the Kell blood group system, KUCI and KANT, and their serologic and spatial association with K11 and KETI
Background The numerous antigens in the Kell blood group system result from missense nucleotide changes in KEL. Antibodies to antigens in this system can be clinically important. We describe six probands whose plasma contained antibodies to high‐prevalence Kell antigens and discuss their relationship. Study Design and Methods Polymerase chain reaction amplification, direct sequencing, restriction fragment length polymorphism assays, hemagglutination, flow cytometry, and protein modeling were performed by standard methods. Results Proband 1 (KUCI) and her serologically compatible sister were heterozygous for a nucleotide change in Exon 11 (KEL*1271C/T; Ala424Val). Proband 2 (KANT) was heterozygous for KEL*1283G/T (Arg428Leu) and KEL*1216C/T (Arg406Stop) in Exon 11. Red blood cells (RBCs) from Proband 1 and her sister were not agglutinated by plasma from Proband 2; however, RBCs from Proband 2 were agglutinated by plasma from Proband 1. Probands 3, 4, 5, and 6 had the KEL*1391C>T change associated with the previously reported KETI– phenotype. Proband 5 was also homozygous for KEL*905T>C encoding the K11–K17+ phenotype. Hemagglutination studies revealed an association between KUCI, KANT, KETI, and K11. Protein modeling indicated that whereas Ala424 and Arg428 are clustered, Val302 and Thr464 are not. Conclusion Ala424 in the Kell glycoprotein is associated with the high‐prevalence Kell antigen, KUCI (ISBT 006032), which is detected by the antibody of Proband 1. Arg428 is associated with the high‐prevalence Kell antigen, KANT (ISBT 006033). The association between KUCI, KANT, KETI, and K11 and the results of protein modeling are discussed.
- 25 February 2013
- Published by Wiley in Transfusion
- Vol. 53 (11) , 2710-2714
The JR blood group system: identification of alleles that alter expression
Background: The ABCG2 gene encodes antigens of the JR blood group system. Red blood cells (RBCs) from individuals homozygous for ABCG2 null alleles are nonreactive with polyclonal and monoclonal anti‐Jra. However, some RBCs have been defined as Jr(a+W/–) or Jr(a–), particularly when tested with polyclonal anti‐Jra. In an effort to resolve these apparent serologic ambiguities, the current study was undertaken.Study Design and Methods: Hemagglutination of RBCs from two individuals known to express a single copy of functional ABCG2 were compared to RBCs from eight unrelated, previously characterized, Jr(a+W/–) donors. Standard polymerase chain reaction–based methods were used to characterize ABCG2 alleles.Results: Two monoclonal anti‐Jra clones agglutinated RBCs from the eight Jr(a+W/–) study subjects. Two of these subjects were homozygous for a missense ABCG2 change (c.1858A; Asp620Asn). Two were heterozygous for two missense changes; one was c.1858G>A and c.421C>A (Asp620Asn; Gln141Lys), and the other was c.1714A>C and c.421C>A (Ser572Arg; Gln141Lys). The remaining four subjects were heterozygous for c.421C>A (Gln141Lys), and for one of four null alleles.Conclusions: We have identified three ABCG2 alleles that are newly associated with weakened Jra expression. One of these is novel, the missense allele c.1714A>C (Ser572Arg) and two that have been previously described c.421C>A (rs2231142; Gln141Lys) and c.1858G>A (rs34783571; Asp620Asn). In addition, we found a novel, presumed null allele, c.1017_1019delCTC (Ser340del).
- 25 February 2013
- Published by Wiley in Transfusion
- Vol. 53 (11) , 2710-2714
The JR blood group system: identification of alleles that alter expression
Background: The ABCG2 gene encodes antigens of the JR blood group system. Red blood cells (RBCs) from individuals homozygous for ABCG2 null alleles are nonreactive with polyclonal and monoclonal anti‐Jra. However, some RBCs have been defined as Jr(a+W/–) or Jr(a–), particularly when tested with polyclonal anti‐Jra. In an effort to resolve these apparent serologic ambiguities, the current study was undertaken.Study Design and Methods: Hemagglutination of RBCs from two individuals known to express a single copy of functional ABCG2 were compared to RBCs from eight unrelated, previously characterized, Jr(a+W/–) donors. Standard polymerase chain reaction–based methods were used to characterize ABCG2 alleles.Results: Two monoclonal anti‐Jra clones agglutinated RBCs from the eight Jr(a+W/–) study subjects. Two of these subjects were homozygous for a missense ABCG2 change (c.1858A; Asp620Asn). Two were heterozygous for two missense changes; one was c.1858G>A and c.421C>A (Asp620Asn; Gln141Lys), and the other was c.1714A>C and c.421C>A (Ser572Arg; Gln141Lys). The remaining four subjects were heterozygous for c.421C>A (Gln141Lys), and for one of four null alleles.Conclusions: We have identified three ABCG2 alleles that are newly associated with weakened Jra expression. One of these is novel, the missense allele c.1714A>C (Ser572Arg) and two that have been previously described c.421C>A (rs2231142; Gln141Lys) and c.1858G>A (rs34783571; Asp620Asn). In addition, we found a novel, presumed null allele, c.1017_1019delCTC (Ser340del).
- 15 October 2012
- Published by Wiley in Transfusion
- Vol. 53 (7) , 1575-1579
The JR blood group system (ISBT 032): molecular characterization of three new null alleles
Background: Jra (ISBT 901005) is a high‐prevalence antigen unassigned to a blood group system. People lacking this antigen have been found in all populations studied but most commonly in Asians. Two recent reports established that ABCG2‐null alleles encode the Jr(a–) phenotype and these studies provided the impetus to study other Jr(a−) individuals.Study Design and Methods: Blood samples were part of our rare donor‐patient collection. DNA was isolated and analyzed by standard techniques.Results: In samples from 13 Jr(a–) study subjects, we found six alleles with nonsense nucleotide changes, three (c.784T, c.1591T, and c.337T) were novel. Twelve of the samples were homozygous for nonsense single‐nucleotide polymorphisms (SNPs): eight were c.376T, two were c.706T, one was c.784T, and one was c.1591T. Each of these alleles predicts a truncated ABCG2 product, Gln126Stop, Arg236Stop, Gly262Stop, and Gln531Stop, respectively. One study subject was heterozygous for two nonsense SNPs: c.337C/T (Arg113Stop) and c.736C/T (Arg246Stop).Conclusions: Jra is the sole antigen in the newly established JR blood group system (ISBT 032001). The previous ISBT designation (901005) is now obsolete. Since ABCG2null alleles define the Jr(a–) phenotype, an explanation for why no antithetical low‐prevalence antigen to Jra has been found, and also why anti‐Jra made by people with any of these JRnull alleles are mutually compatible has been determined. Based on our findings DNA‐based genotyping can be developed to replace the serologic methods that are currently used to identify Jr(a–) blood donors.
- 15 October 2012
- Published by Wiley in Transfusion
- Vol. 53 (7) , 1575-1579
The JR blood group system (ISBT 032): molecular characterization of three new null alleles
Background: Jra (ISBT 901005) is a high‐prevalence antigen unassigned to a blood group system. People lacking this antigen have been found in all populations studied but most commonly in Asians. Two recent reports established that ABCG2‐null alleles encode the Jr(a–) phenotype and these studies provided the impetus to study other Jr(a−) individuals.Study Design and Methods: Blood samples were part of our rare donor‐patient collection. DNA was isolated and analyzed by standard techniques.Results: In samples from 13 Jr(a–) study subjects, we found six alleles with nonsense nucleotide changes, three (c.784T, c.1591T, and c.337T) were novel. Twelve of the samples were homozygous for nonsense single‐nucleotide polymorphisms (SNPs): eight were c.376T, two were c.706T, one was c.784T, and one was c.1591T. Each of these alleles predicts a truncated ABCG2 product, Gln126Stop, Arg236Stop, Gly262Stop, and Gln531Stop, respectively. One study subject was heterozygous for two nonsense SNPs: c.337C/T (Arg113Stop) and c.736C/T (Arg246Stop).Conclusions: Jra is the sole antigen in the newly established JR blood group system (ISBT 032001). The previous ISBT designation (901005) is now obsolete. Since ABCG2null alleles define the Jr(a–) phenotype, an explanation for why no antithetical low‐prevalence antigen to Jra has been found, and also why anti‐Jra made by people with any of these JRnull alleles are mutually compatible has been determined. Based on our findings DNA‐based genotyping can be developed to replace the serologic methods that are currently used to identify Jr(a–) blood donors.
- 13 July 2012
- Published by Wiley in Transfusion
- Vol. 53 (4) , 741-746
RHCE*ceTI encodes partial c and partial e and is often in cis to RHD*DIVa
BACKGROUND: In the Rh blood group system, variant RhD and RhCE express several partial antigens. We investigated RH in samples with partial DIVa that demonstrated weak and variable reactivity with anti‐C.STUDY DESIGN AND METHODS: Standard hemagglutination techniques, polymerase chain reaction–based assays, and RH sequencing were used.RESULTS: DNA analysis showed that six red blood cell (RBC) samples with weak and inconsistent reactivity with anti‐C lacked RHCE*C, but all had RHD*DIVa, which encodes partial D and Goa. We then tested RBCs from 19 Go(a+) cryopreserved samples (confirmed to have RHD*DIVa) with four anti‐C and observed weak variable reactions. RHCE genotyping found all but one of the samples with RHD*DIVa also had RHCE nt 48G>C and 1025C>T, named RHCE*ceTI. Lookback of samples referred for workup and found to have either allele revealed 47 of 55 had both RHD*DIVa and RHCE*ceTI, four had RHD*DIVa without RHCE*ceTI, and four had RHCE*ceTI without RHD*DIVa. Alloanti‐c was found in a patient with c+ RBCs and RHCE*ceTI in trans to RHCE*Ce, and alloanti‐e was found in a patient with e+ RBC and RHCE*ceTI in trans to RHCE*cE. RHD*DIVa in trans to RHD erroneously tested as RHD hemizygous.CONCLUSIONS: RHD*DIVa and RHCE*ceTI almost always, but not invariably, travel together. This haplotype is found in people of African ancestry and the RBCs can demonstrate aberrant reactivity with anti‐C. RHCE*ceTI encodes partial c and e antigens. We confirm that RHD zygosity assays are unreliable in samples with RHD*DIVa.
- 13 July 2012
- Published by Wiley in Transfusion
- Vol. 53 (4) , 741-746
RHCE*ceTI encodes partial c and partial e and is often in cis to RHD*DIVa
BACKGROUND: In the Rh blood group system, variant RhD and RhCE express several partial antigens. We investigated RH in samples with partial DIVa that demonstrated weak and variable reactivity with anti‐C.STUDY DESIGN AND METHODS: Standard hemagglutination techniques, polymerase chain reaction–based assays, and RH sequencing were used.RESULTS: DNA analysis showed that six red blood cell (RBC) samples with weak and inconsistent reactivity with anti‐C lacked RHCE*C, but all had RHD*DIVa, which encodes partial D and Goa. We then tested RBCs from 19 Go(a+) cryopreserved samples (confirmed to have RHD*DIVa) with four anti‐C and observed weak variable reactions. RHCE genotyping found all but one of the samples with RHD*DIVa also had RHCE nt 48G>C and 1025C>T, named RHCE*ceTI. Lookback of samples referred for workup and found to have either allele revealed 47 of 55 had both RHD*DIVa and RHCE*ceTI, four had RHD*DIVa without RHCE*ceTI, and four had RHCE*ceTI without RHD*DIVa. Alloanti‐c was found in a patient with c+ RBCs and RHCE*ceTI in trans to RHCE*Ce, and alloanti‐e was found in a patient with e+ RBC and RHCE*ceTI in trans to RHCE*cE. RHD*DIVa in trans to RHD erroneously tested as RHD hemizygous.CONCLUSIONS: RHD*DIVa and RHCE*ceTI almost always, but not invariably, travel together. This haplotype is found in people of African ancestry and the RBCs can demonstrate aberrant reactivity with anti‐C. RHCE*ceTI encodes partial c and e antigens. We confirm that RHD zygosity assays are unreliable in samples with RHD*DIVa.
- 28 June 2012
- Published by Wiley in Transfusion
- Vol. 53 (3) , 539-544
The low-prevalence Rh antigen STEM (RH49) is encoded by two different RHCE*ce818T alleles that are often in cis toRHD*DOL
BACKGROUND: STEM (RH49) is a low‐prevalence antigen in the Rh blood group system. A scarcity of anti‐STEM has precluded extensive study of this antigen. We report that two alleles with a RHCE*ce818C>T change encode a partial e, and a hrS−, hrB+, STEM+ phenotype and that both alleles are frequently in cis to RHD*DOL1 or RHD*DOL2. STUDY DESIGN AND METHODS: Blood samples were from donors and patients in our collections. Hemagglutination, DNA, and RNA testing was performed by standard techniques. RESULTS: Fourteen STEM+ samples were heterozygous RHCE*ce818C/T: six had RHCE*ceBI and eight had a novel allele, RHCE*ceSM. Eleven were heterozygous for RHD*DOL1 or RHD*DOL2. Eleven samples, previously typed STEM−, had RHCE*ce818C/C (consensus nucleotide). RBCs from informative STEM+ samples were e+/− hrS− hrB+. One person who was heterozygous RHCE*ceBI and RHCE*cE had an anti‐e‐like antibody in her plasma, and one person, who was hemizygous for RHD*DOL2, had anti‐D in her plasma. CONCLUSIONS: We show that two alleles with a RHCE*ce818C>T change (RHCE*ceBI and RHCE*ceSM) encode a hrS− hrB+ STEM+ phenotype. In addition, both alleles are frequently in cis to RHD*DOL1 or RHD*DOL2 and RHCE*ceBI encodes a partial e antigen. In the small cohort of samples tested, RHD*DOL invariably traveled with RHCE*ce818T. Our study also confirmed the presumption that RHD*DOL2, like RHD*DOL1, encodes a partial D antigen and the low‐prevalence antigen DAK.
- 28 June 2012
- Published by Wiley in Transfusion
- Vol. 53 (3) , 539-544
The low-prevalence Rh antigen STEM (RH49) is encoded by two different RHCE*ce818T alleles that are often in cis toRHD*DOL
BACKGROUND: STEM (RH49) is a low‐prevalence antigen in the Rh blood group system. A scarcity of anti‐STEM has precluded extensive study of this antigen. We report that two alleles with a RHCE*ce818C>T change encode a partial e, and a hrS−, hrB+, STEM+ phenotype and that both alleles are frequently in cis to RHD*DOL1 or RHD*DOL2. STUDY DESIGN AND METHODS: Blood samples were from donors and patients in our collections. Hemagglutination, DNA, and RNA testing was performed by standard techniques. RESULTS: Fourteen STEM+ samples were heterozygous RHCE*ce818C/T: six had RHCE*ceBI and eight had a novel allele, RHCE*ceSM. Eleven were heterozygous for RHD*DOL1 or RHD*DOL2. Eleven samples, previously typed STEM−, had RHCE*ce818C/C (consensus nucleotide). RBCs from informative STEM+ samples were e+/− hrS− hrB+. One person who was heterozygous RHCE*ceBI and RHCE*cE had an anti‐e‐like antibody in her plasma, and one person, who was hemizygous for RHD*DOL2, had anti‐D in her plasma. CONCLUSIONS: We show that two alleles with a RHCE*ce818C>T change (RHCE*ceBI and RHCE*ceSM) encode a hrS− hrB+ STEM+ phenotype. In addition, both alleles are frequently in cis to RHD*DOL1 or RHD*DOL2 and RHCE*ceBI encodes a partial e antigen. In the small cohort of samples tested, RHD*DOL invariably traveled with RHCE*ce818T. Our study also confirmed the presumption that RHD*DOL2, like RHD*DOL1, encodes a partial D antigen and the low‐prevalence antigen DAK.
- 13 June 2012
- Published by Wiley in ISBT Science Series
- Vol. 7 (1) , 41-43
ISBT Scientific Series – State of the Art Invited speakerProtein blood group systems: Berlin and beyond
As of July 2010, 24 of the 30 blood group systems recognized by the International Society of Blood Transfusion (ISBT) are protein‐based. These proteins are oriented within the red cell membrane as single pass membrane proteins, multi‐pass proteins, glycosylphosphatidylinositol‐linked proteins, or adsorbed from the plasma. At the 2010 meeting of the ISBT working party on the red cell immunogenetics and blood group terminology, 14 ‘new’ high‐incidence blood group antigens were ratified into 10 of the systems, one antigen was made obsolete, and a new collection was established. Early in 2012, two new protein‐based blood group systems were established. Both are members of the ATP‐binding cassette family of proteins.
- 13 June 2012
- Published by Wiley in ISBT Science Series
- Vol. 7 (1) , 41-43
ISBT Scientific Series – State of the Art Invited speakerProtein blood group systems: Berlin and beyond
As of July 2010, 24 of the 30 blood group systems recognized by the International Society of Blood Transfusion (ISBT) are protein‐based. These proteins are oriented within the red cell membrane as single pass membrane proteins, multi‐pass proteins, glycosylphosphatidylinositol‐linked proteins, or adsorbed from the plasma. At the 2010 meeting of the ISBT working party on the red cell immunogenetics and blood group terminology, 14 ‘new’ high‐incidence blood group antigens were ratified into 10 of the systems, one antigen was made obsolete, and a new collection was established. Early in 2012, two new protein‐based blood group systems were established. Both are members of the ATP‐binding cassette family of proteins.
- 11 July 2011
- Published by Wiley in Transfusion
- Vol. 52 (1) , 39-42
DIII Type 7 is likely the original serologically defined DIIIb
- 11 July 2011
- Published by Wiley in Transfusion
- Vol. 52 (1) , 39-42
DIII Type 7 is likely the original serologically defined DIIIb